drugset / Trial / NCT01522196

A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.

NCT01522196 ↗

Phase 2 Terminated 2 enrolled Anthera Pharmaceuticals
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to determine the effectiveness of A 001 infusion in preventing acute chest syndrome in sickle cell disease (SCD) subjects with vaso-occlusive crisis, fever, and elevated serum C-reactive protein (CRP).

Timeline

Start
2012-02
Primary completion
2012-03
Completion
2012-03

Outcome

Outcome not reported

Stopped: “change in company plans”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Varespladib Small molecule 110 ug/kg Intravenous

Indications